A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

July 16, 2008

Primary Completion Date

April 9, 2009

Study Completion Date

April 9, 2009

Conditions
Atopic Dermatitis
Interventions
DRUG

SUN13834

Low dose, orally 3 times a day (tid) for 28 days of SUN13834

DRUG

Placebo

Placebo, orally (tid) for 28 days of SUN13834

Trial Locations (28)

11790

Derm Research Center of New York, Inc., Stony Brook

19103

Paddington Testing Co, Inc., Philadelphia

23233

Commonwealth Clinical Research Specialists, Inc., Richmond

27157

Wake Forest University Health Sciences - Dermatology Studies, Winston-Salem

27612

Wake Research Associates, LLC, Raleigh

29651

Radiant Research, Inc, Greer

32174

Advanced Dermatology and Cosmetic Surgery, Ormond Beach

33143

Miami Research Associates, Miami

33613

Stedman Clinical Trials, Tampa

35209

Radiant Research, Inc., Birmingham

40217

DermResearch, PLLC, Louisville

43560

Toledo Center for Clinical Research, Sylvania

47713

Deaconess Clinic Downtown Research Institute, Evansville

48038

Michigan Center for Skin Care Research, Clinton Township

71913

Burke Pharmaceutical Research, Hot Springs

73104

Oklahoma University Health Sciences Center, Dermatology Dept, Oklahoma City

75246

Baylor Research Institute of Dermatology Department, Dallas

77845

J & S Studies, Inc, College Station

78258

Dermatology Associates of San Antonio, San Antonio

80220

Horizons Clinical Research Center, LLC, Denver

83704

Northwest Clinical Trials, Boise

84020

Intermountain Clinical Research, Draper

85210

Pivotal Research Center, Mesa

85381

Pivotal Research Center, Peoria

87106

Academic Dermatology, Albuquerque

92123

Therapeutics Clinical Research, San Diego

99204

Premier Clinical Research, Spokane

02919

Clinical Partners, LLC, Johnston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY